We remind investors that in Jan 2014, the court upheld the validity of Endo’s patent (5,464,864) on Frova and ruled that it would be infringed by Mylan’s generic version of the treatment. The court ...

Over the weekend, specialty drugmaker Endo Pharmaceuticals (NASDAQ:ENDP) presented more clinical trial results for its already approved migraine treatment, Frova. Frova was initially launched in 2002 ...

Endo, Vernalis Plc Drug Frova FDA Review Period To Be Extended Additional Three Months Endo Pharmaceuticals Holdings Inc. and Vernalis today announced that the U.S. Food and Drug Administration (FDA) ...

Vernalis and partner Endo Pharmaceuticals have reported the results of a second, confirmatory Phase III trial showing the benefits of their Frova product in menstrual migraine. Vernalis and partner ...

UK biotechnology firm Vernalis said today its application to market Frova drug as a treatment for preventing menstrual migraine in the USA has been accepted for review by the Food and Drug ...

CHADDS FORD, PA--(MARKET WIRE)--Apr 7, 2008 -- Endo Pharmaceuticals Inc., a market leader in pain management and a wholly owned subsidiary of Endo Pharmaceuticals Holdings Inc. (NasdaqGS:ENDP - News), ...

NEW YORK, Sept 30 (Reuters) - Endo Pharmaceuticals and Vernalis said on Sunday the U.S. Food and Drug Administration had identified deficiencies and asked for more information regarding their ...

Jefferson University, Philadelphia, and published today in the journal Neurology, shows that Frova (frovatriptan), a triptan class migraine therapy with a long half life, significantly reduced the ...

The FDA rejects Endo's attempts to expand the Frova label. On Sunday, Endo Pharmaceuticals (NYSE:ENDP) announced that the FDA had issued a "not approvable" letter in response to the company's attempt ...

Endo Pharma presents results from a Phase 3 randomized, double-blind, placebo-controlled clinical trial evaluating FROVA (frovatriptan succinate) 2.5 mg tablets as a six-day preventative treatment in ...

A British drug company said on Monday that a final-stage Phase III study showed that the headache drug Frova helped keep patients free from menstrual-related migraine. Vernalis Plc reported clinical ...